

## Custirsen

<b>Cat. No.:</b>	HY-143230
<b>CAS No.:</b>	890056-27-6
<b>Molecular Weight:</b>	7346
<b>Sequence:</b>	DNA, d(P-thio)([2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2-methoxyethyl)]rG-[2'-O-(2-methoxyethyl)]m5rC-A-G-C-A-G-A-G-T-C-T-T-C-A-[2'-O-(2-methoxyethyl)]m5rU-[2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2-methoxyethyl)]m5rU)
<b>Target:</b>	Apoptosis
<b>Pathway:</b>	Apoptosis
<b>Storage:</b>	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

# Custirsen

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 50 mg/mL (6.81 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		0.1361 mL	0.6806 mL	1.3613 mL
	5 mM		0.0272 mL	0.1361 mL	0.2723 mL
	10 mM		---	---	---

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Custirsen is a highly specific antisense oligonucleotide that inhibits the production of clusterin, an antiapoptotic protein that is upregulated in response to chemotherapy and that confers treatment resistance.

### REFERENCES

[1]. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. *J Natl Cancer Inst.* 2005;97(17):1287-1296.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA